Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma

International Journal of Cancer

Volumn 68, Issue 1, 1996, Pages 93-96

  Ghetie, Maria Ana ^a   Podar, Erika M ^a   Gordon, Brian E ^b   Pantazis, Panayotis ^c   Uhr, Jonathan W ^a   Vitetta, Ellen S ^a,d  

^a University of Texas   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c Stehlin Found for Cancer Research   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAMPTOTHECIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOTOXIN; RICIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; DISSEMINATED CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; IMMUNOTOXINS; LECTINS; LYMPHOMA; MICE; MICE, SCID; RICIN;

EID: 0029982902     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960927)68:1<93::AID-IJC16>3.0.CO;2-7     Document Type: Article

References (24)

1. AKIYAMA, S.-I., GOTTESMAN, M.M., HANOVER, J.A., FITZGERALD, D.J.P., WILLINGHAM, M.C. and PASTAN, I., Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J. cell. Physiol., 120, 271-279 (1984).
2. CHIGNOLA, R., PASTI, M., CANDIANI, C., FRANCESCHI, A., ANSELMI, C., TRIDENTE, G. and COLOMBATTI, M., Escape mechanisms of human leukemic cells to long-term immunotoxin treatment in an in vitro experiment model. Int. J. Cancer, 61, 535-541 (1995).
3. DALTON, W.S., Overcoming the multidrug-resistant phenotype. In: V. DeVita, Jr., S. Hellman and S.A. Rosenberg (eds.), Cancer: principles and practice of oncology (4th ed.), pp. 2655-2666, Lippincott, Philadelphia (1993).
4. ENGERT, A., MARTIN, G., PFREUNDSCHUH, M., AMLOT, P., HSU, S.M., DIEHL, V. and THORPE, P., Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. Cancer Res., 50, 2929-2935 (1990).
5. FITZGERALD, D.J., WILLINGHAM, M.C., CARDARELLI, C.O., HAMADA, H., TSURUO, T., GOTTESMAN, M.M. and PASTAN, I., A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. nat. Acad. Sci. (Wash.), 84, 4288-4292 (1987).
6. GHETIE, M.-A., RICHARDSON, J., TUCKER, T., JONES, D., UHR, J.W. and VITETTA, E.S., Disseminated or localized growth of a human B cell tumor (Daudi) in SCID mice. Int. J. Cancer, 45, 481-485 (1990).
7. GHETIE, M.A., TUCKER, K., PODAR, E., GORDON, B., RICHARDSON, J., PANTAZIS, P., UHR, J.W. and VITETTA, E.S., Combination therapy (chemotherapy plus an immunotoxin cocktail) can eradicate minimal disease and significantly extend the survival of SCID mice with disseminated Daudi lymphoma. The 9th International Congress of Immunology (Abstract 5256), San Francisco, CA, p. 886 (1995).
8. GHETIE, M.-A., TUCKER, K., RICHARDSON, J., UHR, J.W. and VITETTA, E.S., Eradication of minimal disease in SCID mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood, 84, 702-707 (1994).
9. GHETIE, M.A. and VITETTA, E.S., Recent developments in immunotoxin therapy. Curr. Opin. Immunol., 6, 707-714 (1994).
10. HARRISON, D.J., Molecular mechanisms of drug resistance in tumours. J. Pathol., 175, 7-12 (1995).
11. JAFFRÉZOU, J.-P. and LAURENT, G., The intriguing link between modulation of both multidrug resistance and ligand-toxin conjugate cytotoxicity. FEBS J., 323, 191-197 (1993).
12. JAFFRÉZOU, J.-P., LEVADE, T., KUHLEIN, E., THURNEYSSEN, O., CHIRON, M., GRANDJEAN, H., CARRIERE, D. and LAURENT, G., Enhancement of ricin A chain immunotoxin activity by perhexiline on established and fresh leukemic cells. Cancer Res., 50, 5558-5566 (1990).
13. JAFFRÉZOU, J.-P., LEVADE, T., THURNEYSSEN, O., CHIRON, M., BORDIER, C., ATTAL, M., CHATELAIN, P. and LAURENT, G., In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction. Cancer Res., 52, 1352-1359 (1992).
14. JANSEN, B., VALLERA, D.A., JASZCZ, W.B., NGUYEN, D. and KERSEY, J.H., Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res., 52, 1314-1321 (1992).
15. KALBFLEISCH, J.D. and PRENTICE, R.L., The statistical analysis of failure time data, p. 1-321, Wiley, New York (1980).
16. KURATOMI, Y., AKIYAMA, S.-I., ONO, M., SHIRAISHI, N., SHIMADA, T., OHKUMA, S. and KUWANO, M., Thioridazine enhances lysosomal accumulation of epidermal growth factor and toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin. Exp. Cell Res., 162, 436-448 (1986).
17. LIDOR, Y.J., O'BRIANT, K.C., XU, F.J., HAMILTON, T.C., OZOLS, R.F. and BAST, R.C., JR., Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J. clin. Invest., 92, 2440-2447 (1993).
18. O'CONNOR, R., LIU, C., FERRIS, C.A., TEICHER, B.A., GUILD, B.C., CORVI, C., LIU, Y., ARCECI, R.J., GOLDMACHER, V.S., LAMBERT, J.M. and BLÄTTLER, W.A., Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood, 86, 4586-4294 (1995).
19. O'CONNOR, R., LIU, C., TEICHER, B.A., SHAH, S.A. and BLÄTTLER, W.A., Anti-B4-blocked ricin as a candidate to reverse multidrug-resistance in B-cell tumors. [Abstract] Blood, 82, 140a (1993).
20. SAUSVILLE, E.A. and 14 OTHERS, Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood, 85, 3457-3464 (1995).
21. SHAH, S.A., HALLORAN, P.M., FERRIS, C.A., LEVINE, B.A., BOURRET, L.A., GOLDMACHER, V.S. and BLÄTTLER, W.A., Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res., 53, 1360-1367 (1993).
22. SPIERS, A.S.D., Multi drug resistance, the MDR gene, and the law of maximum perversity as it applies to oncology: an hypothesis. Hematol. Oncol., 12, 155-161 (1994).
23. WINKLER, U., GOTTSTEIN, C., SCHÖN, G., KAPP, U., WOLF, J., HANSMANN, M.-L., BOHLEN, H., THORPE, P., DIEHL, V. and ENGERT, A., Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood, 83, 466-475 (1994).
24. YUEN, A.R. and SIKIC, B.I., Multidrug resistance in lymphomas. J. clin. Oncol., 12, 2453-2459 (1994).